Charles River Laboratories International, Inc. $CRL Stock: Signaturefd LLC Grows Position

Signaturefd LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 563.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,865 shares of the medical research company’s stock after purchasing an additional 7,529 shares during the period. Signaturefd LLC’s holdings in Charles River Laboratories International were worth $2,615,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of CRL. Dimensional Fund Advisors LP grew its position in Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after purchasing an additional 210,260 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after buying an additional 54,500 shares during the last quarter. Amundi raised its holdings in shares of Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after buying an additional 492,301 shares during the last quarter. Van Berkom & Associates Inc. boosted its stake in shares of Charles River Laboratories International by 11.2% during the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock worth $86,449,000 after buying an additional 50,462 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Charles River Laboratories International by 2.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 225,314 shares of the medical research company’s stock worth $51,099,000 after buying an additional 6,401 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on CRL shares. Deutsche Bank Aktiengesellschaft boosted their price target on Charles River Laboratories International from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Friday, September 25th. TD Cowen upped their price objective on Charles River Laboratories International from $300.00 to $325.00 and gave the company a “buy” rating in a research note on Friday, September 25th. CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research report on Monday, July 20th. Jefferies Financial Group lifted their target price on Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Finally, Evercore set a $330.00 target price on Charles River Laboratories International in a report on Friday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average target price of $302.33.

Charles River Laboratories International Price Performance

CRL stock opened at $345.08 on Monday. The firm has a 50 day moving average of $294.35 and a 200-day moving average of $233.67. Charles River Laboratories International, Inc. has a 12-month low of $146.20 and a 12-month high of $351.21. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The company has a market cap of $16.47 billion, a price-to-earnings ratio of -71.15, a PEG ratio of 3.23 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,046 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at approximately $1,264,241. The trade was a 51.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 33,561 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $9,478,800. This trade represents a 51.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 94,127 shares of company stock worth $26,776,516 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.